Macrolide-resistant Mycoplasma pneumoniae, North Dakota 2024.

A cluster of macrolide-resistant Mycoplasma pneumoniae causing community-acquired pneumonia was observed in children in North Dakota in 2024. Suspicion was raised by non-response to macrolides, with confirmation via a PCR assay. Prompt improvement occurred after initiation of alternative antibiotics.

Testing for in an era of antimicrobial resistance.

Antimicrobial resistance in has reached alarming levels and is compromising traditional empiric treatment of . Antimicrobial susceptibility testing is routinely performed for infectious diseases when there is a risk of resistance and is now recommended to guide therapy for . This mini-review overviews the current diagnostics for with a focus on tests that enable susceptibility-guided treatment, including molecular tests performed directly on stool and endoscopically collected specimens.

Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.

The epidemiology of macrolide resistance in () in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories.